Afexa Life Sciences Inc.
TSX : FXA

Afexa Life Sciences Inc.

June 23, 2011 08:00 ET

Best Buy Canada Ltd. CFO Joins Afexa Board

EDMONTON, ALBERTA--(Marketwire - June 23, 2011) - Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA), maker of COLD-FX®, announced the appointment of Annalisa King, Senior Vice President and CFO of Best Buy Canada Ltd., to its Board of Directors. Ms. King brings the board complement to eight.

"We are delighted to have Ms. King join our Board of Directors. Afexa is an innovative and forward-looking science Company, and our lead product COLD-FX is a remarkable success in the marketplace. Our strategic plans and rigorous product development pipeline require that we have Board members with deep and diverse business experience, leadership skills, and financial acumen. Annalisa brings these qualities and more to our Board, and we are pleased she has accepted our invitation to join the Board," said William White, Chair of the Board of Afexa.

Ms. King is a dynamic business thought-leader in the areas of corporate finance and business transformation. She is an inductee of Canada's Most Powerful Women: Top 100 Hall of Fame, and a champion of leadership development for women.

As Senior Vice President and Chief Financial Officer of Best Buy Canada Ltd. in Vancouver B.C., Ms. King oversees the strategic planning, budget, reporting, accounting, auditing, decision support, and financial analysis business areas. She also carries the responsibility for overseeing the Information Technology, Legal, and Real Estate functions within Best Buy and provides analysis and guidance focused on achieving the company's key fiscal targets.

Prior to joining Best Buy Canada Ltd., Ms. King was the Senior Vice President of Business Transformation for Maple Leaf Foods in Toronto. She has held senior positions, primarily in finance, throughout her career at consumer packaged goods companies Kraft and Pillsbury Canada

The appointment is effective June 24, 2011.

About Afexa Life Sciences Inc.

Afexa Life Sciences Inc., founded in 1992, strives to deliver the most trusted health brand on the planet through pioneering evidence-based natural medicines that empower people to achieve their health potential. The Company's patented ChemBioPrint® discovery and standardization technology enables the development of effective and safe medicines from complex natural sources, while ensuring reliable health benefits and batch-to-batch consistency. COLD-FX®, a ChemBioPrint product, is the Company's flagship product and Canada's leading over-the-counter (OTC) cold and flu remedy. It is officially indicated in Canada to help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system. COLD-FX has a product license (NPN) and is supported by scientific evidence, including randomized, double-blind, placebo-controlled clinical trials.

Contact Information